Signal transduction and molecular targets of selected flavonoids

Antioxidants and Redox Signaling

Volumn 19, Issue 2, 2013, Pages 163-180

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 DEOXYKAEMPFEROL; 6,7,4' TRIHYDROXY ISOFLAVONE; 7,3',4' TRIHYDROXY ISOFLAVONE; DELPHINIDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; EQUOL; ERIODICTYOL; FLAVONOID; ISORHAMNETIN; KAEMPFEROL; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYRICETIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; QUERCETIN; QUERCETIN 3 METHYL ETHER; RAF PROTEIN; RAS PROTEIN; RED WINE EXTRACT; UNCLASSIFIED DRUG;

CANCER INHIBITION; CARCINOMA; CELL PROLIFERATION; CRYSTALLOGRAPHY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; RED WINE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER;

ANIMALS; FLAVONOIDS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHYTOCHEMICALS; SIGNAL TRANSDUCTION;

EID: 84879159740     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5251     Document Type: Review

References (153)

1. Arts IC, Hollman PC, Bueno De Mesquita HB, Feskens EJ, and Kromhout D. Dietary catechins and epithelial cancer incidence: the Zutphen elderly study. Int J Cancer 92: 298-302, 2001.
2. Bagchi M, Milnes M, Williams C, Balmoori J, Ye X, Stohs S, and Bagchi D. Acute and chronic stress-induced oxidative gastrointestinal injury in rats, and the protective ability of a novel grape seed proanthocyanidin extract. Nutr Res 19: 1189-1199, 1999.
3. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, and Fotsis T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3-kinase activity. Cancer Res 64: 7936-7946, 2004.
4. Balasubramanian S and Govindasamy S. Inhibitory effect of dietary flavonol quercetin on 7,12-dimethylbenz[a] anthracene-induced hamster buccal pouch carcinogenesis. Carcinogenesis 17: 877-879, 1996.
5. Ball AR, Jr., Bos TJ, Loliger C, Nagata LP, Nishimura T, Su H, Tsuchie H, and Vogt PK. Jun: oncogene and transcriptional regulator. Cold Spring Harb Symp Quant Biol 53 Pt 2: 687-693, 1988.
6. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37 Suppl 4: S16-S22, 2001.
7. Benbrook DM and Jones NC. Heterodimer formation between CREB and JUN proteins. Oncogene 5: 295-302, 1990.
8. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Jr., Brice MD, Rodgers JR, Kennard O, Shimanouchi T, and Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 112: 535-542, 1977.
9. Bode AM and Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 1: 181-188, 2000.
10. Bode AM and Dong Z. Signal transduction pathways: Targets for green and black tea polyphenols. In: Recent Research Developments in Cancer, edited by Pandalai SG. Trivandrum, India: Transworld Research Network, 2002, pp. 73-83.
11. Bode AM and Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003: RE2, 2003.
12. Bode AM and Dong Z. Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol 36: 66-77, 2003.
13. Bode AM and Dong Z. Cancer prevention by food factors through targeting signal transduction pathways. Nutrition 20: 89-94, 2004.
14. Bode AM and Dong Z. Targeting signal transduction pathways by chemopreventive agents. Mutat Res 555: 33-51, 2004.
15. Bode AM and Dong Z. Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol 79: 237-297, 2005.
16. Bode AM and Dong Z. Molecular and cellular targets. Mol Carcinog 45: 422-430, 2006.
17. Bode AM and Dong Z. Cancer prevention research-then and now. Nat Rev Cancer 9: 508-516, 2009.
18. Bode AM and Dong Z. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res (Phila) 2: 514-517, 2009.
19. Bode AM and Dong Z. Modulation of cell signal transduction by tea and ginger. In: Dietary Modulation of Cell Signaling Pathways, edited by Surh Y-J, Cadenas E, Dong Z, and Packer L. New York: CRC press, Taylor & Francis group, 2009, pp. 45-74.
20. Bode AM and Dong Z. Signal transduction molecules as targets for cancer prevention. Sci Signal 2: mr2, 2009.
21. Bode AM and Dong Z. Effects of dietary effectors on signal transduction pathways related to cancer prevention. In: Nutritional Genomics-The Impact of Dietary Regulation of Gene Function on Human Disease, edited by Bidlack WR and Rodriguez RL. New York: CRC Press, 2012, pp. 243-268.
22. Bravo L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56: 317-333, 1998.
23. Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH, Bode AM, Lee HJ, and Dong Z. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res 70: 2415-2423, 2010.
24. Chen H, Yao K, Nadas J, Bode AM, Malakhova M, Oi N, Li H, Lubet RA, and Dong Z. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One 7: e38261, 2012.
25. Cho SY, Park SJ, Kwon MJ, Jeong TS, Bok SH, Choi WY, Jeong WI, Ryu SY, Do SH, Lee CS, Song JC, and Jeong KS. Quercetin suppresses proinflammatory cytokines production through MAP kinases andNF-kappaB pathway in lipopolysaccharide-stimulated macrophage. Mol Cell Biochem 243: 153-160, 2003.
26. Cho YY, Yao K, Kim HG, Kang BS, Zheng D, Bode AM, and Dong Z. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res 67: 8104-8112, 2007.
27. Cho YY, Yao K, Pugliese A, Malakhova ML, Bode AM, and Dong Z. A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res 69: 4398-4406, 2009.
28. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, and Dong Z. Phosphorylation of histone H3 at serine 10 Is indispensable for neoplastic cell transformation. Cancer Res 65: 5818-5827, 2005.
29. Choi HS, Kang BS, Shim JH, Cho YY, Choi BY, Bode AM, and Dong Z. Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J 22: 113-126, 2008.
30. Chu EC and Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 10: RA235-RA241, 2004.
31. Chun OK, Kim DO, and Lee CY. Superoxide radical scavenging activity of the major polyphenols in fresh plums. J Agric Food Chem 51: 8067-8072, 2003.
32. Ciardiello F and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
33. Cohen DR and Curran T. fra-1: a serum-inducible, cellular immediate-early gene that encodes a fos-related antigen. Mol Cell Biol 8: 2063-2069, 1988.
34. Corcoran MP, McKay DL, and Blumberg JB. Flavonoid basics: chemistry, sources, mechanisms of action, and safety. J Nutr Gerontol Geriatr 31: 176-189, 2012.
35. Cowley S, Paterson H, Kemp P, and Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994.
36. Craig WJ. Phytochemicals: guardians of our health. J Am Diet Assoc 97: S199-S204, 1997.
37. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, and Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567, 2008.
38. de Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV, and Aoyama H. Phosphoprotein levels, MAPK activities and NFkappaB expression are affected by fisetin. J Enzyme Inhib Med Chem 22: 439-444, 2007.
39. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, and Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.
40. Dominguez-Sola D and Dalla-Favera R. PINning down the c-Myc oncoprotein. Nat Cell Biol 6: 288-289, 2004.
41. Ermakova S, Choi BY, Choi HS, Kang BS, Bode AM, and Dong Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem 280: 16882-16890, 2005.
42. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, Bode AM, and Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein. Cancer Res 66: 9260-9269, 2006.
43. Frei B and Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133: 3275S-3284S, 2003.
44. Garcia R, Gonzalez CA, Agudo A, and Riboli E. High intake of specific carotenoids and flavonoids does not reduce the risk of bladder cancer. Nutr Cancer 35: 212-214, 1999.
45. Garcia-Closas R, Agudo A, Gonzalez CA, and Riboli E. Intake of specific carotenoids and flavonoids and the risk of lung cancer in women in Barcelona, Spain. Nutr cancer 32: 154-158, 1998.
46. German JB and Walzem RL. The health benefits of wine. Annu Revi Nutr 20: 561-593, 2000.
47. Goldbohm RA, Hertog MG, Brants HA, van Poppel G, and van den Brandt PA. Consumption of black tea and cancer risk: a prospective cohort study. J Natl Cancer Inst 88: 93-100, 1996.
48. Guo JY, Li X, Browning JD, Jr., Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, and MacDonald RS. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 134: 179-182, 2004.
49. Gupta S, Hastak K, Ahmad N, Lewin JS, and Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 98: 10350-10355, 2001.
50. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, and Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9: 68-76, 2006.
51. Hakkinen SH, Karenlampi SO, Heinonen IM, Mykkanen HM, and Torronen AR. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem 47: 2274-2279, 1999.
52. Hardy G, Hardy I, and McElroy B. Nutraceuticals: a pharmaceutical viewpoint: I. Curr Opin Clin Nutr Metab Care 5: 671-677, 2002.
53. Harris DM, Besselink E, Henning SM, Go VL, and Heber D. Phytoestrogens induce differential estrogen receptor alphaor Beta-mediated responses in transfected breast cancer cells. Exp Biol Med 230: 558-568, 2005.
54. Hayakawa S, Saeki K, Sazuka M, Suzuki Y, Shoji Y, Ohta T, Kaji K, Yuo A, and Isemura M. Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 285: 1102-1106, 2001.
55. He Z, Cho YY, Ma WY, Choi HS, Bode AM, and Dong Z. Regulation of ultraviolet B-induced phosphorylation of histone H3 at serine 10 by Fyn kinase. J Biol Chem 280: 2446-2454, 2005.
56. He Z, Tang F, Ermakova S, Li M, Zhao Q, Cho YY, Ma WY, Choi HS, Bode AM, Yang CS, and Dong Z. Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol Carcinog 47: 172-183, 2008.
57. Heijnen CG, Haenen GR, van Acker FA, van der Vijgh WJ, and Bast A. Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicol In Vitro 15: 3-6, 2001.
58. Hertog MG, Feskens EJ, Hollman PC, Katan MB, and Kromhout D. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. Nutr Cancer 22: 175-184, 1994.
59. Hong WK. General keynote: the impact of cancer chemoprevention. Gynecol Oncol 88: S56-S58, 2003.
60. Huang MT, Xie JG, Wang ZY, Ho CT, Lou YR, Wang CX, Hard GC, and Conney AH. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 57: 2623-2629, 1997.
61. Hwang MK, Song NR, Kang NJ, Lee KW, and Lee HJ. Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin. Int J Biochem Cell Biol 41: 1592-1600, 2009.
62. Hynes NE and Boulay A. The mTOR pathway in breast cancer. J Mammary Gland Biol Neoplasia 11: 53-61, 2006.
63. Hynes NE and Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
64. Irwin JJ and Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182, 2005.
65. Jimeno A and Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochimt Biophys Acta 1766: 217-229, 2006.
66. Joannou GE, Kelly GE, Reeder AY, Waring M, and Nelson C. A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. J Steroid Biochem Mol Biol 54: 167-184, 1995.
67. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, Bode AM, Bowden GT, Lee HJ, and Dong Z. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 68: 6021-6029, 2008.
68. Jung SK, Lee KW, Byun S, Lee EJ, Kim JE, Bode AM, Dong Z, and Lee HJ. Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo. Carcinogenesis 31: 911-917, 2010.
69. Jung SK, Lee KW, Kim HY, Oh MH, Byun S, Lim SH, Heo YS, Kang NJ, Bode AM, Dong Z, and Lee HJ. Myricetinsuppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 79: 1455-1461, 2010.
70. Kang NJ, Lee KW, Kwon JY, Hwang MK, Rogozin EA, Heo YS, Bode AM, Lee HJ, and Dong Z. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/ extracellular signal-regulated kinase signaling. Cancer Prev Res (Phila) 1: 522-531, 2008.
71. Kang NJ, Lee KW, Rogozin EA, Cho YY, Heo YS, Bode AM, Lee HJ, and Dong Z. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282: 32856-32866, 2007.
72. Kavanagh KT, Hafer LJ, Kim DW, Mann KK, Sherr DH, Rogers AE, and Sonenshein GE. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 82: 387-398, 2001.
73. Kelly GE, Nelson C, Waring MA, Joannou GE, and Reeder AY. Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta 223: 9-22, 1993.
74. Kim JE, Kwon JY, Lee DE, Kang NJ, Heo YS, Lee KW, and Lee HJ. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 77: 412-421, 2009.
75. Kim JE, Lee DE, Lee KW, Son JE, Seo SK, Li J, Jung SK, Heo YS, Mottamal M, Bode AM, Dong Z, and Lee HJ. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila) 4: 582-591, 2011.
76. Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 89: 529-538, 2003.
77. Kinoshita T, Lepp Z, Kawai Y, Terao J, and Chuman H. An integrated database of flavonoids. Biofactors 26: 179-188, 2006.
78. Ko CH, Shen SC, Lee TJ, and Chen YC. Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 4: 281-290, 2005.
79. Kong AN, Owuor E, Yu R, Hebbar V, Chen C, Hu R, and Mandlekar S. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 33: 255-271, 2001.
80. Kovary K and Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 11: 4466-4472, 1991.
81. Kulling SE, Honig DM, and Metzler M. Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J Agric Food Chem 49: 3024-3033, 2001.
82. Kulling SE, Honig DM, Simat TJ, and Metzler M. Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein. J Agric Food Chem 48: 4963-4972, 2000.
83. Kumamoto T, Fujii M, and Hou DX. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem 332: 33-41, 2009.
84. Kumamoto T, Fujii M, and Hou DX. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett 275: 17-26, 2009.
85. Kwon JY, Lee KW, Kim JE, Jung SK, Kang NJ, Hwang MK, Heo YS, Bode AM, Dong Z, and Lee HJ. Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase. Carcinogenesis 30: 1932-1940, 2009.
86. Lee DE, Lee KW, Byun S, Jung SK, Song N, Lim SH, Heo YS, Kim JE, Kang NJ, Kim BY, Bowden GT, Bode AM, Lee HJ, and Dong Z. 7,3,4-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet Binduced skin cancer by targeting Cot and MKK4. J Biol Chem 286: 14246-14256, 2011.
87. Lee DE, Lee KW, Jung SK, Lee EJ, Hwang JA, Lim TG, Kim BY, Bode AM, Lee HJ, and Dong Z. 6,7,4-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis 32: 629-635, 2011.
88. Lee DE, Lee KW, Song NR, Seo SK, Heo YS, Kang NJ, Bode AM, Lee HJ, and Dong Z. 7,3,4-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P + mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase. J Biol Chem 285: 21458-21466, 2010.
89. Lee KM, Lee KW, Byun S, Jung SK, Seo SK, Heo YS, Bode AM, Lee HJ, and Dong Z. 5-deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer. Cancer Prev Res (Phila) 3: 454-465, 2010.
90. Lee KM, Lee KW, Jung SK, Lee EJ, Heo YS, Bode AM, Lubet RA, Lee HJ, and Dong Z. Kaempferol inhibits UVBinduced COX-2 expression by suppressing Src kinase activity. Biochem Pharmacol 80: 2042-2049, 2010.
91. Lee KW, Bode AM, and Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11: 211-218, 2011.
92. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, Bode AM, Lee HJ, and Dong Z. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 68: 946-955, 2008.
93. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, Lee HJ, Surh YJ, Bowden GT, and Dong Z. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28: 1918-1927, 2007.
94. Li J, Mottamal M, Li H, Liu K, Zhu F, Cho YY, Sosa CP, Zhou K, Bowden GT, Bode AM, and Dong Z. Quercetin-3-methyl ether suppresses proliferation of mouse epidermal JB6 P + cells by targeting ERKs. Carcinogenesis 33: 459-465, 2012.
95. Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, D'Alessio A, Normano N, Dong Z, and Bode AM. Quercetin-3-methyl ether inhibits lapatinib-sensitive and-resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. Mol Carcinog 52: 134-143, 2013.
96. Li M, He Z, Ermakova S, Zheng D, Tang F, Cho YY, Zhu F, Ma WY, Sham Y, Rogozin EA, Bode AM, Cao Y, and Dong Z. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 16: 598-605, 2007.
97. Li ZG, Shimada Y, Sato F, Maeda M, Itami A, Kaganoi J, Komoto I, Kawabe A, and Imamura M. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamineinduced esophageal tumorigenesis in F344 rats. Int J Oncol 21: 1275-1283, 2002.
98. Liu K Cho YY, Yao K, Nadas J, Kim DJ, Cho EJ, Lee MH, Pugliese A, Zhang J, Bode AM, and Dong Z Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. J BiolChem286: 2057-2066
99. Kim JE, Kwon JY, Lee DE, Kang NJ, Heo YS, Lee KW, and Lee HJ. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 77: 412-421, 2009.
100. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, and Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66: 4410-4418, 2006.
101. Mahadevan LC, Willis AC, and Barratt MJ. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 65: 775-783, 1991.
102. Malakhova M, Kurinov I, Liu K, Zheng D, D'Angelo I, Shim JH, Steinman V, Bode AM, and Dong Z. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase PLoS One 4: e8044, 2009.
103. Malakhova M, Tereshko V, Lee SY, Yao K, Cho YY, Bode A, and Dong Z. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2. Nat Struct Mol Biol 15: 112-113, 2008.
104. Matsui M, Tokuhara M, Konuma Y, Nomura N, and Ishizaki R. Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene 5: 249-255, 1990.
105. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11: 494-502, 2007.
106. Meric-Bernstam F and Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287, 2009.
107. Miean KH and Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 49: 3106-3112, 2001.
108. Mosesson Y and Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 14: 262-270, 2004.
109. Mukhtar H, Das M, Khan WA, Wang ZY, Bik DP, and Bickers DR. Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a)anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosoureainduced skin tumorigenesis in mice. Cancer Res 48: 2361-2365, 1988.
110. Nishikura K and Murray JM. Antisense RNA of proto-oncogene c-fos blocks renewed growth of quiescent 3T3 cells. Mol Cell Biol 7: 639-649, 1987.
111. Nishina H, Sato H, Suzuki T, Sato M, and Iba H. Isolation and characterization of fra-2, an additional member of the fos gene family. Proc Natl Acad Sci U S A 87: 3619-3623, 1990.
112. Northrop JP, Ullman KS, and Crabtree GR. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NFAT) complex. J Biol Chem 268: 2917-2923, 1993.
113. O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, and Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 551: 245-254, 2004.
114. Okuno H, Suzuki T, Yoshida T, Hashimoto Y, Curran T, and Iba H. Inhibition of jun transformation by a mutated fos gene: design of an anti-oncogene. Oncogene 6: 1491-1497, 1991.
115. Palermo CM, Westlake CA, and Gasiewicz TA. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 44: 5041-5052, 2005.
116. Panel E. Scientific Opinion on the substantiation of health claims related to various food(s)/food constituent(s) and protection of cells from premature aging, antioxidant activity, antioxidant content and antioxidant properties, and protection of DNA, proteins and lipids from oxidative damage pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 8: 1489, 2010.
117. Pietta PG. Flavonoids as antioxidants. J Nat Prod 63: 1035-1042, 2000.
118. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem 18: 427-442, 2007.
119. Ranganathan R, Lu KP, Hunter T, and Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89: 875-886, 1997.
120. Ransone LJ and Verma IM. Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol 6: 539-557, 1990.
121. Rolo-Naranjo A, Codorniu-Hernandez E, and Ferro N. Quantum Chemical Associations Ligand-Residue: Their Role to Predict Flavonoid Binding Sites in Proteins. J Chem Inf Model 50: 924-933, 2010.
122. Ryder K, Lanahan A, Perez-Albuerne E, and Nathans D. jun-D: a third member of the jun gene family. Proc Natl Acad Sci U S A 86: 1500-1503, 1989.
123. Ryder K, Lau LF, and Nathans D. A gene activated by growth factors is related to the oncogene v-jun. Proc Natl Acad Sci U S A 85: 1487-1491, 1988.
124. Ryo A, Nakamura M, Wulf G, Liou YC, and Lu KP. Pin1 regulates turnover and subcellular localization of betacatenin by inhibiting its interaction with APC. Nat Cell Biol 3: 793-801, 2001.
125. Sah JF, Balasubramanian S, Eckert RL, and Rorke EA. Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 279: 12755-12762, 2004.
126. Sakata K, Hirose Y, Qiao Z, Tanaka T, and Mori H. Inhibition of inducible isoforms of cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett 199: 139-145, 2003.
127. Sazuka M, Isemura M, and Isemura S. Interaction between the carboxyl-terminal heparin-binding domain of fibronectin and (-)-epigallocatechin gallate. Biosci Biotechnol Biochem 62: 1031-1032, 1998.
128. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3: 1133-1137, 2004.
129. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, and Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999.
130. Shim JH, Choi HS, Pugliese A, Lee SY, Chae JI, Choi BY, Bode AM, and Dong Z. Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase. J Biol Chem 283: 28370-28379, 2008.
131. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, Bode AM, Yang CS, and Dong Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein. Cancer Prev Res (Phila) 3: 670-679, 2010.
132. Soleas GJ, Grass L, Josephy PD, Goldberg DM, and Diamandis EP. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem 35: 119-124, 2002.
133. Spencer JP. Flavonoids: modulators of brain function? Br J Nutr 99 E Suppl 1: ES60-ES77, 2008.
134. Suetsugi M, Su L, Karlsberg K, Yuan YC, and Chen S. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res 1: 981-991, 2003.
135. Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y, Sonobe MH, Kameda T, Ichinose M, Miki K, and Iba H. Analysis of AP-1 function in cellular transformation pathways. J Virol 68: 3527-3535, 1994.
136. Suzuki Y and Isemura M. Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett 173: 15-20, 2001.
137. Tachibana H, Koga K, Fujimura Y, and Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 11: 380-381, 2004.
138. Tian WX. Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 13: 967-977, 2006.
139. Urusova DV, Shim JH, Kim DJ, Jung SK, Zykova TA, Carper A, Bode AM, and Dong Z. Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev Res 4: 1366-1377, 2011.
140. Walle UK and Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos 30: 564-569, 2002.
141. Weir B, Zhao X, and Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438, 2004.
142. Widyarini S, Husband AJ, and Reeve VE. Protective effect of the isoflavonoid equol against hairless mouse skin carcinogenesis induced by UV radiation alone or with a chemical cocarcinogen. Photochem Photobiol 81: 32-37, 2005.
143. Williams RJ, Spencer JP, and Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 36: 838-849, 2004.
144. Williamson MP, McCormick TG, Nance CL, and Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allergy Clin Immunol 118: 1369-1374, 2006.
145. Wulf G, Finn G, Suizu F, and Lu KP. Phosphorylationspecific prolyl isomerization: is there an underlying theme? Nat Cell Biol 7: 435-441, 2005.
146. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, and Lu KP. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20: 3459-3472, 2001.
147. Yamamoto Y and Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142, 2001.
148. Yamane T, Nakatani H, Kikuoka N, Matsumoto H, Iwata Y, Kitao Y, Oya K, and Takahashi T. Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Cancer 77: 1662-1667, 1996.
149. Yang CS, Yang GY, Landau JM, Kim S, and Liao J. Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression. Exp Lung Res 24: 629-639, 1998.
150. Yin Z, Henry EC, and Gasiewicz TA. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 48: 336-345, 2009.
151. Yuan R, Kay A, Berg WJ, and Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2: 45, 2009.
152. Zerial M, Toschi L, Ryseck RP, Schuermann M, Muller R, and Bravo R. The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity. EMBO J 8: 805-813, 1989.
153. Zhang Y, Feng XH, and Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 394: 909-913, 1998.